Login / Signup

Cost-Effectiveness of Polygenic Risk Scores to Guide Statin Therapy for Cardiovascular Disease Prevention.

Michel KiflenAnn LeShihong MaoRicky LaliSukrit NarulaFeng XieGuillaume Paré
Published in: Circulation. Genomic and precision medicine (2022)
This study suggests that using PRS alongside existing guidelines might be cost-effective for CVD. Stronger predictiveness combined with decreased cost of PRS could further improve cost-effectiveness, providing an economic basis for its inclusion into clinical care.
Keyphrases
  • cardiovascular disease
  • healthcare
  • palliative care
  • type diabetes
  • coronary artery disease
  • clinical practice
  • quality improvement
  • cardiovascular events
  • low density lipoprotein